Ashley Grossman was awarded an Open Exhibition to St Catharine’s College, Cambridge, but left to complete a degree in Psychology and Social Anthropology at the University of London, and then entered University College London where he received a First Class degree in Anatomy, and the University Gold Medal from UCHMS. Following ‘house jobs’ at UCHMS, St Thomas’ hospital and the National Hospital in Queen Square, London, he started in the Dept. of Endocrinology at St Bartholomew’s Hospital and medical school, eventually becoming Professor of Neuroendocrinology at Barts and the London School of Medicine in 1993. He moved to OCDEM, Churchill Hospital, in 2011 where he was appointed Professor of Endocrinology at the University of Oxford, and in 2012 Fellow of Green-Templeton College. Most recently, he has started work as Consultant on neuroendocrine tumours at the Royal Free Hospital, London, in the ENETS Centre of Excellence. He was awarded MRCP in 1978, FRCP in 1990, MD in 1992 and a Fellow of the Academy of Medical Sciences in 1999. He has published some 480 peer-reviewed papers and 350 chapters and reviews, originally in the field of hypothalamo-pituitary regulation, but more recently in hypothalamic and pituitar
It is vital for all of us involved in endocrinology and diabetes to keep abreast of advances in the various fields which will help those for whom we are responsible, our patients. As an endocrinologist with a particular interest in endocrine oncology, I am aware that attending specialist meetings and workshops is to be at the forefront of work on these fields, but almost all of us will see patients with a whole a variety of different conditions encompassed within the broad church of our disciplines. For that reason it is particularly welcome to that in this edition of European Endocrinology we have extremely useful review articles on such common international problems as obesity and diabetes. This is especially important as those of us working in the developed world may seem to be isolated from those patients, the majority in the developing world, with obesity, type 2 diabetes, and the so-called overlap now often informally referred to as diabesity. In this issue Perez-Pevida and Miras look at the latest progress on obesity management worldwide, while Mbanya and colleagues overview the access to the new recombinant and analogue insulins in terms of their worldwide availability. There is little point in developing wonderful new therapies if they are unavailable for one reason or another, including finance, to those who most need it.
In more specialised areas, Neil Gittoes surveys what is happening at present in bone disorders, especially osteoporosis, while Shrijal Baxi reveals how the progressive concept of a web-based protocol is showing many deficiencies in practice.
Finally, a case report demonstrates yet another cause of Takotsubo cardiomyopathy, thyroxine over-replacement. We hope you find this issue both enjoyable and useful.